{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:01:57Z","timestamp":1777417317682,"version":"3.51.4"},"reference-count":10,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2001,12,1]],"date-time":"2001-12-01T00:00:00Z","timestamp":1007164800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2001,12]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To report a case of aggravation of glaucoma associated with the use of fluvoxamine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CASE SUMMARY:<\/jats:title>\n                    <jats:p>A 66-year-old white woman diagnosed with narrow-angle glaucoma showed an increase in intraocular pressure and experienced orbital pain and blurred vision after the initiation of fluvoxamine for tension-type headache. These symptoms disappeared and intraocular pressure normalized after withdrawal of this drug.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION:<\/jats:title>\n                    <jats:p>Aggravation of narrow-angle glaucoma is a well-known adverse effect of tricyclic antidepressants. Because this adverse effect had been rarely reported to date with selective serotonin-reuptake inhibitors (paroxetine and fluoxetine), we used fluvoxamine in our patient. The disappearance of ocular symptoms and the normalization of intraocular pressure two days after stopping fluvoxamine suggest a possible relationship between fluvoxamine and aggravation of glaucoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Fluvoxamine should be considered as a drug that can induce or aggravate narrow-angle glaucoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1z440","type":"journal-article","created":{"date-parts":[[2003,6,3]],"date-time":"2003-06-03T17:52:04Z","timestamp":1054662724000},"page":"1565-1566","source":"Crossref","is-referenced-by-count":22,"title":["Aggravation of Glaucoma with Fluvoxamine"],"prefix":"10.1177","volume":"35","author":[{"given":"F\u00e9lix Javier","family":"Jim\u00e9nez-Jim\u00e9nez","sequence":"first","affiliation":[{"name":"F\u00e9lix Javier Jim\u00e9nez-Jim\u00e9nez MD PhD, Associate Professor of Neurology, Departamento de Medicina-Neurolog\u00eda, Hospital Pr\u00edncipe de Asturias, Universidad de Alcal\u00e1, Carretera de Meco S\/N, E-28805, Alcal\u00e1 de Henares; Director, Neuro-Magister S.L., Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Ort\u00ed-Pareja","sequence":"additional","affiliation":[{"name":"Miguel Ort\u00ed-Pareja MD PhD, Senior Neurologist, Neuro-Magister S.L."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Mart\u00edn","family":"Zurdo","sequence":"additional","affiliation":[{"name":"Jos\u00e9 Mart\u00edn Zurdo MD, Senior Neurologist, Neuro-Magister S.L."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2001,12,1]]},"reference":[{"key":"bibr-bibr1-aph.1Z440","first-page":"177","volume-title":"Headache","author":"Schoenen J","year":"1997"},{"key":"bibr-bibr2-aph.1Z440","first-page":"532","volume-title":"Oxford textbook of psychiatry","author":"Gelder M","year":"1996"},{"key":"bibr-bibr3-aph.1Z440","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.314.7091.1387"},{"key":"bibr-bibr4-aph.1Z440","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v58n0307b"},{"key":"bibr-bibr5-aph.1Z440","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.81.3.252"},{"key":"bibr-bibr6-aph.1Z440","doi-asserted-by":"publisher","DOI":"10.1038\/eye.1999.196"},{"key":"bibr-bibr7-aph.1Z440","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2000.106"},{"key":"bibr-bibr8-aph.1Z440","first-page":"436","volume":"25","author":"Ahmad S","year":"1991","journal-title":"Drug Intell Clin Pharm"},{"key":"bibr-bibr9-aph.1Z440","first-page":"130","volume":"21","author":"Aragona M","year":"1998","journal-title":"Clin Neuropharmacol"},{"key":"bibr-bibr10-aph.1Z440","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1Z440","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1Z440","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:04:27Z","timestamp":1777374267000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1Z440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,12]]},"references-count":10,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2001,12]]}},"alternative-id":["10.1345\/aph.1Z440"],"URL":"https:\/\/doi.org\/10.1345\/aph.1z440","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,12]]}}}